GILEAD SCIENCES ANNOUNCES TWO PHASE 3 RANDOMISED STUDIES TO EVALUATE THE SAFETY AND ANTIVIRAL ACTIVITY OF REMDESIVIR (GS-5734) IN PARTICIPANTS WITH MODERATE TO SEVERE COVID-19
- Remdesivir is an investigational agent ? it is not approved anywhere?globally and has not been demonstrated to be safe or effective for any use.
- The UK is one of the countries where Gilead is running clinical trials to evaluate remdesivir?for the treatment of COVID-19
- Liverpool University Hospitals NHS Foundation Trust, Royal Free London NHS Foundation Trust,
- Sheffield Teaching Hospitals NHS Foundation Trust (adult services), Manchester Royal Infirmary,
- Wythenshawe Hospital, Hull University Teaching Hospitals NHS Trust, London North West University
- Healthcare NHS Trust, The Pennine Acute Hospitals NHS Trust, University College London Hospitals
- NHS Foundation Trust, King?s College Hospital NHS Foundation Trust, Royal Lancaster Infirmary,
- Glasgow Queen Elizabeth University Hospital, Edinburgh Western General Hospital, University
- Hospitals Plymouth NHS Trust, Imperial College Healthcare NHS Trust.